Source: Circulation-cardiovascular interventions. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, ANGIOPLASTIA TRANSLUMINAL PERCUTÂNEA CORONÁRIA, TROMBOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DILLINGER, Jean-Guillaume e NICOLAU, Jose C. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, v. 11, n. 6, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084. Acesso em: 09 jun. 2024.APA
Dillinger, J. -G., & Nicolau, J. C. (2018). Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, 11( 6). doi:10.1161/CIRCINTERVENTIONS.118.006084NLM
Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 jun. 09 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084Vancouver
Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 jun. 09 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084
